Year |
Citation |
Score |
2020 |
Rathod M, Kelkar M, Valvi S, Salve G, De A. FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy. Molecular Therapy Oncolytics. 19: 93-104. PMID 33102692 DOI: 10.1016/J.Omto.2020.08.015 |
0.675 |
|
2018 |
Rathod M, Kelkar M, Salvi G, De A. PO-022 Benzamide class of HDACi differentially enhance sodium iodide symporter expression in breast cancer Esmo Open. 3: A236. DOI: 10.1136/esmoopen-2018-EACR25.557 |
0.658 |
|
2018 |
Agrawal S, Kelkar M, De A, Kulkarni AR, Gandhi MN. Newly emerging mesoporous strontium hydroxyapatite nanorods: microwave synthesis and relevance as doxorubicin nanocarrier Journal of Nanoparticle Research. 20: 230. DOI: 10.1007/S11051-018-4335-Y |
0.511 |
|
2017 |
Kelkar MG, Thakur B, Derle A, Chatterjee S, Ray P, De A. Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer. Breast Cancer Research and Treatment. PMID 28528452 DOI: 10.1007/s10549-017-4297-2 |
0.598 |
|
2016 |
Kelkar MG, Senthilkumar K, Jadhav S, Gupta S, Ahn BC, De A. Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation. Scientific Reports. 6: 19341. PMID 26777440 DOI: 10.1038/Srep19341 |
0.683 |
|
2016 |
Agrawal S, Kelkar M, De A, Kulkarni AR, Gandhi MN. Surfactant free novel one-minute microwave synthesis, characterization and cell toxicity study of mesoporous strontium hydroxyapatite nanorods Rsc Advances. 6: 94921-94926. DOI: 10.1039/C6Ra21708G |
0.493 |
|
2012 |
Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, Kumar S, Pandey M, Singh RK, Ray P, Natarajan R, Kelkar M, De A, Choudhary B, Raghavan SC. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 151: 1474-87. PMID 23260137 DOI: 10.1016/J.Cell.2012.11.054 |
0.553 |
|
2012 |
Kelkar M, De A. Bioluminescence based in vivo screening technologies. Current Opinion in Pharmacology. 12: 592-600. PMID 22954534 DOI: 10.1016/J.Coph.2012.07.014 |
0.501 |
|
Show low-probability matches. |